Investment Rating - The investment rating for the company is "Outperform the Market" [5][30]. Core Insights - The company reported a 3.6% year-on-year increase in revenue and a 7.7% increase in net profit for the first three quarters, with total revenue of 674 million yuan and net profit of 151 million yuan [1]. - The optical microscope segment is expected to see a recovery in growth, driven by domestic demand for high-end products and the company's successful development of a domestic four-color laser confocal microscope, breaking a 34-year foreign monopoly [2]. - The company is focusing on diversifying its business, with significant growth in the medical optics sector and ongoing projects in semiconductor optics, which are expected to contribute to future revenue growth [3]. Financial Performance Summary - For the first three quarters, the company achieved a gross margin of 40.32%, with a slight increase of 1.25 percentage points year-on-year [1]. - The projected revenue for 2025-2027 is expected to reach 1.057 billion yuan, 1.304 billion yuan, and 1.632 billion yuan respectively, with corresponding net profits of 284 million yuan, 359 million yuan, and 456 million yuan [4][3]. - The company's earnings per share (EPS) is projected to grow from 2.56 yuan in 2025 to 4.11 yuan in 2027, indicating a positive trend in profitability [4].